Target intelligence / Profile preview

Host Immune & Vasculature Systems

Molecular classification
Other
01

Overview

The Host Immune & Vasculature Systems represent a complex physiological network rather than a single molecular target. This category encompasses the dynamic interactions between the host's immune cells and the endothelial lining of the blood vessels, which together regulate inflammation, nutrient transport, and tissue repair (Pober & Sessa, Nature Reviews Immunology, 2007). In pathological conditions such as sepsis, severe viral infections like COVID-19, and malignancy, the dysregulation of this interface leads to systemic inflammatory response syndrome (SIRS), vascular leakage, and coagulopathy (Teuwen et al., Nature Reviews Immunology, 2020). Drugs targeting this system typically act on specific signaling molecules like Vascular Endothelial Growth Factor (VEGF) or Interleukin-6 (IL-6) to restore vascular integrity or dampen hyper-inflammation (Tanaka et al., Cold Spring Harbor Perspectives in Biology, 2014). Because it involves multiple cell types and signaling pathways, it is classified as a systemic physiological target rather than a discrete protein (Carmeliet, Nature, 2005). Understanding this crosstalk is vital for developing therapies that balance effective immune defense with the prevention of vascular-mediated organ damage (Mantovani et al., Nature, 2008).

Other names
Immune-Vascular InterfaceHost Defense and Circulatory SystemsNeuro-Immune-Vascular interactions
02

Mechanism of action

Modulation of systemic inflammatory cascades, inhibition of angiogenic growth factors, stabilization of vascular endothelium, and regulation of leukocyte extravasation.

03

Biological functions

Immune responseAngiogenesisInflammationHemostasisLeukocyte trafficking
04

Disease associations

InfectionCancerCardiovascular diseaseSepsisAutoimmune disease
05

Safety considerations

Increased risk of opportunistic infectionsSecondary hypertensionThrombotic or bleeding complicationsImpaired wound healingCytokine release syndrome
06

Interacting drugs

Bevacizumab

5 more in the full profile.

07

Biomarkers

C-reactive protein (CRP)Interleukin-6 (IL-6)Vascular endothelial growth factor (VEGF)D-dimerProcalcitoninSoluble VCAM-1

Beyond the preview

Go deeper on Host Immune & Vasculature Systems.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Host Immune & Vasculature Systems.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call